RESUMEN
This paper reports the applicability of two-phase and three-phase hollow fiber based liquid-phase microextraction (HF-LPME) for the extraction of hydrochlorothiazide (HYD) and triamterene (TRM) from human urine. The HYD in two-phase HF-LPME is extracted from 24 mL of the aqueous sample into an organic phase with microliter volume located inside the pores and lumen of a polypropylene hollow fiber as acceptor phase, but the TRM in three-phase HF-LPME is extracted from aqueous donor phase to organic phase and then back-extracted to the aqueous acceptor phase, which can be directly injected into HPLC for analysis. Under optimized conditions preconcentration factors of HYD and TRM were obtained as 128 and 239, respectively. The calibration curves were linear (R(2) ≥ 0.995) in the concentration range of 1.0-100 µg/L for HYD and 2.0-100 µg/L for TRM. The limits of detection for HYD and TRM were 0.5 µg/L. The intra-day and inter-day RSD based on four replicates were obtained as ≤5.8 and ≤9.3%, respectively. The methods were successfully applied for determining the concentration of the drugs in urine samples. Copyright © 2015 John Wiley & Sons, Ltd.
Asunto(s)
Diuréticos/aislamiento & purificación , Hidroclorotiazida/aislamiento & purificación , Microextracción en Fase Líquida/métodos , Triantereno/aislamiento & purificación , Diuréticos/orina , Humanos , Hidroclorotiazida/orina , Triantereno/orinaRESUMEN
Melamine (MAM) was employed as a pseudo template to prepare a molecularly imprinted polymer monolithic column which presents the ability of selective recognition to Triamterene (TAT), whose structure was similar to that of MAM. Methacrylic acid and ethylene glycol dimethacrylate were applied as functional monomer and cross-linker, respectively, during the in situ polymerization process. Chromatographic behaviors were evaluated, the results indicated that the molecularly imprinted polymer monolithic column possessed excellent affinity and selectivity for TAT, and the imprinting factor was high up to 3.99 when 7:3 of ACN/water v/v was used as mobile phase. In addition, the dissociation constant and the binding sites were also determined by frontal chromatography as 134.31 µmol/L and 132.28 µmol/g, respectively, which demonstrated that the obtained molecularly imprinted polymer monolith had a high binding capacity and strong affinity ability to TAT. Furthermore, biological samples could be directly injected into the column and TAT was enriched with the optimized mobile phase. These assays gave recovery values higher than 91.60% with RSD values that were always less than 3.5%. The molecularly imprinted monolithic column greatly simplified experiment procedure and can be applied to preconcentration, purification, and analysis of TAT in biological samples.
Asunto(s)
Cromatografía/métodos , Polímeros/química , Triantereno/sangre , Triantereno/orina , Triazinas/química , Cromatografía/instrumentación , Humanos , Impresión Molecular , Polimerizacion , Polímeros/síntesis químicaRESUMEN
In competition sports, a diuretic is a substance widely prohibited by the World Anti-Doping Agency (WADA). In this paper, a sensitive, rapid and convenient analytical method for the determination of acidic [furosemide (FUROS) and bumetanide (BUMET)] and basic [triamterene (TRIAM)] diuretics in human urine was developed by hollow fiber-based liquid-liquid-liquid microextraction (LLLME) coupled with HPLC-UV. The LLLME conditions, such as the organic extraction solvent, the acidity and basicity of the donor- and acceptor-phases, stirring speed, extraction time and ionic strength, were studied in detail. Under the optimum conditions, the linear ranges of furosemide, bumetanide and triamterene were 1.2-250, 5.0-250 and 5.0-500 ng mL(-1), respectively. The detection limits were 0.5 ng mL(-1) for furosemide, 1.2 ng mL(-1) for bumetanide and 2.0 ng mL(-1) for triamterene. The LLLME obtained a great improvement of the detection limits for all the analytes considered here, to the ng mL(-1) level, which almost reaches the level of the LC-MS method. This new LLLME method provided very high enrichments: 117-fold for furosemide, 175-fold for bumetanide and 68-fold for triamterene. Since the hollow fiber membrane was sealed, it could be used for extracting the diuretics directly from 'dirty' human urine samples without any clean-up procedures. With LLLME-HPLC, the corresponding recoveries ranged from 79.2 to 109% with the RSDs not exceeding 5.5% for the three diuretics in the spiked urine samples. The method was successfully applied to analyse the amounts of the three diuretics in real urine samples of volunteers after oral drug-taking. This new method proves to be sensitive and reliable and thus renders a very suitable means for the determination of trace diuretics in human urine based on the common HPLC instrument.
Asunto(s)
Diuréticos/orina , Doping en los Deportes , Bumetanida/orina , Fraccionamiento Químico/métodos , Cromatografía Líquida de Alta Presión/métodos , Furosemida/orina , Humanos , Masculino , Sensibilidad y Especificidad , Triantereno/orinaRESUMEN
Confirmation of medication adherence is a challenge in clinical practice and essential for the accurate diagnosis of resistant hypertension. Although it is well established that drug adherence is critical for controlling blood pressure, there are still difficulties applying a simple, inexpensive, and reliable assessment of adherence in the clinical setting. We aimed to test a simple method to assess adherence in resistant hypertensive (RH) patients. A pilot study with normotensives or mild/moderate hypertensive subjects was performed to provide a fluorescence cutoff point for adherence. After that, 21 patients referred to the Resistant Hypertension Clinic had triamterene prescribed and were monitored for a 30-day period. We conducted two unannounced randomly selected home visits for urine collection to test drug intake that day. Office, home and 24-hour ambulatory blood pressure, biochemical data, and the 8-item Morisky Medication Adherence Scale (MMAS-8) were systematically acquired. According to adherence indicated by urine fluorescence, subjects were divided into adherent and nonadherent groups. We found 57% of nonadherence. No differences were found between groups regarding baseline characteristics or prescribed medications; Kappa's test showed concordance between adherence through MMAS-8 items and fluorescence (kappa = 0.61; 95% confidence interval: 0.28-0.94; P = .005). Nonadherent patients had higher office (81 ± 11 vs. 73 ± 6 mm Hg, P = .03), 24-hour ambulatory blood pressure monitoring (75 ± 9 vs. 66 ± 7 mm Hg, P = .01), and home blood pressure measurement (77 ± 9 vs. 67 ± 8 mm Hg, P = .01) diastolic blood pressure than their counterparts. Nonadherence to antihypertensive therapy is high in patients with RH, even when assessed in clinics specialized in this condition. Fluorometry to detect a drug in the urine of RH patients is safe, easy, and reliable method to assess adherence.
Asunto(s)
Antihipertensivos/uso terapéutico , Vasoespasmo Coronario/tratamiento farmacológico , Vasoespasmo Coronario/psicología , Diuréticos/uso terapéutico , Hipertensión/tratamiento farmacológico , Hipertensión/psicología , Cumplimiento de la Medicación , Anciano , Antihipertensivos/administración & dosificación , Antihipertensivos/orina , Determinación de la Presión Sanguínea , Monitoreo Ambulatorio de la Presión Arterial , Vasoespasmo Coronario/orina , Diuréticos/administración & dosificación , Diuréticos/orina , Estudios de Factibilidad , Femenino , Fluorometría , Humanos , Hipertensión/orina , Masculino , Persona de Mediana Edad , Proyectos Piloto , Sensibilidad y Especificidad , Triantereno/administración & dosificación , Triantereno/uso terapéutico , Triantereno/orinaRESUMEN
A high performance liquid chromatographic (HPLC) method was proposed for the simultaneous determination of four drugs for kidney disease, enalapril, triamterene, furosemide and valsartan. After proteins being removed by acetone precipitation method, freeze drying and redissolving in mobile phase, the urine samples were analyzed by HPLC. Chromatographic separation was performed on a WondaSil C18-WR (150 mm x 4.6 mm, 5 µm) in gradient elution mode using 10.0 mmol/L ammonium acetate aqueous solution (pH 3.90) and acetonitrile as mobile phases at a flow rate of 1.0 mL/min. The detection wavelength was set at 254 nm. Under the optimized conditions, good linearities were obtained in the range of 0.15-300 mg/L, 0.05-100 mg/L, 0.75-750 mg/L, 0.05-100 mg/L, and the detection limits were 1.38 x 10(-2), 7. 67x103, 3.69x 10-2, 1. 16x 10-2 mg/L for enalapril, triamterene, furosemide and valsartan, respectively. The recoveries were in the range of 89.49%-99.20% with the relative standard deviations (RSDs) among 4.12%-9.44%. The method is simple, accurate and effective, and the results showed the method is applicable for the analysis of the four drugs for kidney diseases in real urine samples.
Asunto(s)
Enalapril/orina , Furosemida/orina , Enfermedades Renales/tratamiento farmacológico , Triantereno/orina , Valsartán/orina , Cromatografía Líquida de Alta Presión , HumanosRESUMEN
Through precipitation polymerization, three monodisperse molecularly imprinted polymers (MIPs) containing imprints of 2,4-diamino-6-methyl-1,3,5-triazine (DM), cyromazine (CY) or trimethoprim (TM), were synthesized using methacrylic acid as functional monomer, divinylbenzene as cross-linker, and a mixture of acetonitrile-toluene (90/10, v/v) as porogen. The morphology and selectivity of the MIPs were characterized and compared systematically. The MIPs had the best specific binding in pure acetonitrile, and the data of adsorption experiment were fitted well with Langmuir and Freundlich model. In addition, DM-MIPs showed the excellent binding and multi-recognition capability for CY, melamine (ME), triamterene (TA) and TM, and the binding capacity were 7.18, 7.56, 5.66 and 5.45µmol/g, respectively. Due to the pseudo template and the ability of multi-recognition, DM-MIPs as sorbent material could avoid the effect of template leakage on quantitative analysis. Therefore, DM-MIPs were used as a solid-phase extraction material to enrich ME, CY, TA and TM from different bio-matrix samples for high performance liquid chromatography analysis. Under the optimized conditions, the recoveries of three spiked levels in different bio-matrix samples were ranged from 80.9% to 91.5% with RSD≤4.2 (n=3).
Asunto(s)
Microesferas , Polimerizacion , Triantereno/aislamiento & purificación , Triazinas/aislamiento & purificación , Trimetoprim/aislamiento & purificación , Humanos , Límite de Detección , Microscopía Electrónica de Rastreo , Triantereno/orina , Triazinas/orina , Trimetoprim/orinaRESUMEN
Earlier studies of triamterene (T) disposition in man have reported hydroxytriamterene (T-OH) and hydroxytriamterene sulfate (T-O-SO3H) conjugate to be the major metabolites. We describe T kinetics through use of an HPLC method and confirm that after hydroxylation, T is rapidly converted to T-O-SO3H. The intermediate T-OH metabolite could not be detected in urine or plasma. Plasma concentrations of T-O-SO3H exceeded those of T by sevenfold to 26-fold, whereas concentrations of that metabolite in the urine were fourfold to thirteenfold higher than those of the parent. Renal clearance of T was 314.5 +/- 121.6 ml/min, exceeding that of the metabolite, which was 206.1 +/- 93.6 ml/min. Coadministration of hydrochlorothiazide increased urine flow and urinary pH, but it did not affect renal clearance of the parent drug or the metabolite. T bioavailability from capsules was poorer and more variable than that from a suspension. Hydrochlorothiazide did not influence the bioavailability of T.
Asunto(s)
Triantereno/metabolismo , Absorción , Administración Oral , Disponibilidad Biológica , Biotransformación , Cápsulas , Cromatografía Líquida de Alta Presión , Interacciones Farmacológicas , Humanos , Hidroclorotiazida/farmacología , Concentración de Iones de Hidrógeno , Hidroxilación , Cinética , Masculino , Suspensiones , Triantereno/orinaRESUMEN
Triamterene is extensively metabolized by the liver and undergoes important presystemic elimination in normal subjects after oral doses. We examined triamterene disposition in eight healthy controls and seven patients with cirrhosis and ascites. A specific and sensitive HPLC assay was used to measure concentrations of triamterene and of its major metabolite p-hydroxy-triamterene sulfate (OH-T-S). Apparent oral clearance of triamterene in controls averaged 1617 +/- 219 ml/min. Plasma concentration of OH-T-S was 7.2 +/- 1.1 times that of the parent compound (estimated by the ratio AUCOH -T-S/ AUCtriamterene ). Urinary recovery of OH-T-S accounted for 45% of the triamterene dose. There was 92% reduction in apparent oral clearance of triamterene (134 +/- 42 ml/min) in patients with cirrhosis. The ratio AUCOH -T-S/ AUCtriamterene fell to 0.55 +/- 0.2, and urinary recovery of OH-T-S accounted for only 15% of the dose. These changes in triamterene kinetics in patients with cirrhosis resulted in prolongation of its natriuretic effect, which lasted for up to 48 hr, whereas it was only 8 hr in the controls. These observations reinforce the concept that cirrhosis is associated with a markedly impaired disposition of drugs that have a large first-pass effect.
Asunto(s)
Cirrosis Hepática/metabolismo , Triantereno/metabolismo , Adulto , Femenino , Humanos , Masculino , Tasa de Depuración Metabólica , Persona de Mediana Edad , Natriuresis/efectos de los fármacos , Potasio/sangre , Potasio/orina , Triantereno/análogos & derivados , Triantereno/sangre , Triantereno/farmacología , Triantereno/orinaRESUMEN
A three-treatment, single-dose, crossover bioequivalence study was conducted in healthy volunteers to compare urinary drug recovery following administration of hydrochlorothiazide tablets, the currently marketed capsule formulation of triamterene and hydrochlorothiazide (Dyazide), and a new tablet preparation of these active ingredients (Maxzide). No significant differences were observed in the urinary recovery of hydrochlorothiazide after the administration of hydrochlorothiazide tablets and Maxzide tablets. However, only about one-half as much hydrochlorothiazide was recovered following the administration of Dyazide capsules. Similarly, the urinary recovery of triamterene and the sulfate ester of hydroxy-triamterene after administration of Dyazide capsules was approximately one-half the levels observed after giving the new tablet formulation. The clinical consequences of the limited bioavailability of the active ingredients of Dyazide are discussed.
Asunto(s)
Antihipertensivos/orina , Hidroclorotiazida/orina , Triantereno/orina , Adulto , Disponibilidad Biológica , Combinación de Medicamentos/administración & dosificación , Combinación de Medicamentos/orina , Evaluación de Medicamentos , Humanos , Hidroclorotiazida/administración & dosificación , Masculino , Distribución Aleatoria , Equivalencia Terapéutica , Triantereno/administración & dosificaciónRESUMEN
As triamterene users may form kidney stones containing deposits of triamterene and its metabolites, we studied urinary excretion to detect any altered metabolism of triamterene in these patients. We found no significant differences between patients and matched control subjects in total recovery, hourly excretion patterns, and concentrations of triamterene and its sulfate metabolite. Approximately half of all subjects tested revealed urine concentrations of the sulfate metabolite that exceeded the observed solubility limit.
Asunto(s)
Cálculos Renales/orina , Triantereno/orina , Adulto , Diuresis/efectos de los fármacos , Femenino , Humanos , Cálculos Renales/inducido químicamente , Masculino , Persona de Mediana Edad , Triantereno/administración & dosificación , Triantereno/efectos adversos , Triantereno/análogos & derivadosRESUMEN
Two capillary electrophoresis methods have been developed for the direct determination of triamterene and its main metabolite hydroxytriamterene sulfate in human urine. Analytes were detected using conventional UV detection as well as laser-induced fluorescence (LIF) detection with an HeCd-laser operating at a wavelength of 325 nm. The results of both detection techniques were compared. Indeed, the limit of quantification was eightfold lower using LIF detection (50 ng/ml) in comparison to UV detection (400 ng/ml). As no interference due to endogenous urine compounds was observed, direct urine analysis was feasible. Analysis was very simple and fast-one run could be performed within less than 10 min (CE-UV method) and 2.5 min (CE-LIF method), respectively. Both assays were fully validated and applied to urine samples from a human volunteer. The results of the application of the CE-LIF method to human urine samples are presented in this publication.
Asunto(s)
Diuréticos/orina , Electroforesis Capilar/métodos , Espectrometría de Fluorescencia/métodos , Triantereno/análogos & derivados , Triantereno/orina , Humanos , Rayos Láser , Reproducibilidad de los Resultados , Espectrofotometría UltravioletaRESUMEN
The first rapid and highly sensitive high-performance liquid chromatographic (HPLC) assay for triamterene, hydroxytriamterene, and hydroxytriamterene sulfate is reported. Plasma samples were processed by protein precipitation, while urine was used untreated. Three different solvent systems were used to analyze (a) triamterene in plasma (30% acetonitrile, pH 4.0; internal standard: furosemide; sensitivity limit: 1 ng/mL); (b) hydroxytriamterene and hydroxytriamterene sulfate in plasma (12% acetonitrile, pH 5.5; internal standard: cefamandole; sensitivity limits: 20 and 2 ng/mL, respectively) and (c) triamterene, hydroxytriamterene, and hydroxytriamterene sulfate in urine (13% acetonitrile, pH 5.3; internal standard: hydroflumethiazide; sensitivity limits: 0.04 microgram/mL, 0.5 microgram/mL, and 0.1 microgram/mL, respectively). Fluorescence detection of compounds was performed at 365-nm excitation and 440-nm emission wavelengths. Recovery of triamterene and its metabolites from plasma was complete, and calibration curves were linear. Intraday variation was less than 6% except for the lowest plasma concentration. The assay procedure has already been used in several pharmacokinetic studies.
Asunto(s)
Triantereno/análogos & derivados , Triantereno/análisis , Cromatografía Líquida de Alta Presión/métodos , Humanos , Plasma/análisis , Espectrofotometría Ultravioleta/métodos , Triantereno/sangre , Triantereno/orinaRESUMEN
We examined the occurrence of crystals and casts in the urine of healthy subjects after administration of triamterene and the site of crystal formation in experimental animals. Twenty out of twenty healthy subjects had abundant triamterene crystals and casts in acid urine after receiving a single 100 mg dose. Casts were present in the urine from 2-11 hours after administration of the diuretic. Cast formation occurred in acidic urine and was prevented by alkalinization of the urine with potassium citrate. Animal studies showed that crystallization and cast formation occurred in the medullary and papillary collecting ducts of the rat kidney. These findings provide a possible explanation for the reported nephrotoxicity of triamterene, particularly when given to patients who are receiving non-steroidal anti-inflammatory agents.
Asunto(s)
Riñón/efectos de los fármacos , Triantereno/efectos adversos , Orina/efectos de los fármacos , Adulto , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Cristalización , Interacciones Farmacológicas , Femenino , Humanos , Concentración de Iones de Hidrógeno , Masculino , Persona de Mediana Edad , Ratas , Triantereno/administración & dosificación , Triantereno/orinaRESUMEN
Although triamterene has been in clinical use for over 30 years, the linearity of triamterene kinetics was not systematically tested. Moreover, although triamterene is mostly applied concomitantly with thiazide-type diuretics the interaction of triamterene (TA) with hydrochlorothiazide (HCT) is subject to a controversial discussion. Therefore, the aim of this study was to examine the dose linearity of TA and the pharmacokinetic and pharmacodynamic interaction of triamterene and hydrochlorothiazide. In the first study 10 healthy volunteers received 0, 12.5, 25, 50, and 100 mg triamterene orally in a balanced crossover design. In the second study 0, 25, and 50 mg TA with 12.5, and 25 mg HCT, respectively, were administered to 12 healthy volunteers. Urine volume and concentration of sodium, TA, hydroxytriamterene sulfate (OH-TA ester), and HCT were measured by flame photometry and thin-layer chromatography, respectively. The observation period for each treatment was 3 days and the drug was given on the second day. Sodium excretion was increased by both drugs. Renal excretion of both TA and OH-TA ester seemed to be reduced at higher doses. However, statistical evaluation revealed no significant (p = 0.37, and p = 0.20, respectively) deviation from linearity. Renal excretion of HCT was not affected by TA and vice versa. However, renal excretion of OH-TA ester is significantly reduced when HCT is administered concomitantly. The renal excretion rate of sodium can be described by a common Emax model when the effects of the excretion rates of both TA and HCT are additive. It is concluded that the pharmacokinetics of TA is linear within the tested dose range and that pharmacodynamic additivity of HCT and TA is not due to a pharmacokinetic interaction. The results support the hypothesis of a sequential nephron blockade for both drugs acting on different tubular segments.
Asunto(s)
Antihipertensivos/farmacología , Antihipertensivos/farmacocinética , Diuréticos/farmacología , Diuréticos/farmacocinética , Hidroclorotiazida/farmacología , Hidroclorotiazida/farmacocinética , Triantereno/farmacología , Triantereno/farmacocinética , Adulto , Antihipertensivos/administración & dosificación , Estudios Cruzados , Diuréticos/administración & dosificación , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Interacciones Farmacológicas , Femenino , Humanos , Hidroclorotiazida/administración & dosificación , Túbulos Renales/efectos de los fármacos , Modelos Lineales , Masculino , Sodio/orina , Triantereno/administración & dosificación , Triantereno/análogos & derivados , Triantereno/orinaRESUMEN
The resolution of binary mixtures of triamterene (TAT) and leucovorin (LV) by application of first-derivative spectrophotometry and by application of Partial Least Squares calibration (PLS-1) was performed. Triamterene is determined in presence of leucovorin directly in the absorption spectra at 358 nm, and leucovorin is determined in the first-derivative spectra at 305.6 nm, zero-crossing of the triamterene. The mean recovery values in urine samples were 102 and 97% for TAT and LV, respectively. Partial Least Squares calibration (PLS-1) multivariate calibration of spectrophotometric data, have been applied to the determination of these compounds in serum and in urine without pretreatment of the samples. The absorption spectra of samples of serum or urine, spiked with triamterene and/or leucovorin, were used to perform the optimization of the calibration matrices by PLS-1 method. Mean recovery values were of 107 and 108% for TAT and LV in serum samples, and 98 and 91% for TAT and LV in urine samples.
Asunto(s)
Diuréticos/análisis , Leucovorina/análisis , Triantereno/análisis , Calibración , Diuréticos/sangre , Diuréticos/orina , Humanos , Leucovorina/sangre , Leucovorina/orina , Espectrofotometría Ultravioleta/métodos , Medicina Deportiva , Triantereno/sangre , Triantereno/orinaRESUMEN
Triamterene, a diuretic drug used in combination with other drugs for the treatment of hypertension, was found in the blood and urine of a fatal aircraft accident victim. The extraction and identification of triamterene is difficult. It exhibits poor extraction efficiency using some standard base-extraction procedures, and the parent drug is unsuitable for analysis using gas chromatography. In this case, a thin-layer chromatography solvent system and high-performance liquid chromatography were used to identify and quantitate triamterene in blood and urine. Triamterene is a strong absorber in the ultraviolet region and has an unusual UV spectrum, which simplifies the identification and quantitation of this substance by high-performance liquid chromatography.
Asunto(s)
Accidentes de Aviación , Triantereno/sangre , Triantereno/orina , Cromatografía de Gases , Cromatografía Líquida de Alta Presión , Cromatografía en Capa Delgada , Resultado Fatal , Humanos , Espectrofotometría UltravioletaRESUMEN
A major metabolic pathway for triamterene (a potassium sparing diuretic) is aromatic hydroxylation followed by sulphate conjugation. Diflunisal (a salicylate anti-inflammatory agent) also undergoes sulphate conjugation of its phenolic group as a major pathway. We investigated the possible effect of diflunisal on the elimination of triamterene (competition for phenolic sulphonation) in six healthy volunteers by studying the disposition of single doses of triamterene (100 mg) taken alone and in the presence of steady-state levels of diflunisal. Diflunisal coadministration (500 mg b.i.d.) had no effect on the pharmacokinetics of triamterene itself. However, plasma AUC of p-hydroxytriamterene sulphate was greater (4.6 times), and its renal clearance lower (0.24 times), in the presence of diflunisal. There was no change in the formation clearance or protein binding of p-hydroxytriamterene sulphate in the presence of diflunisal. The data point to competition for renal excretory pathways rather than sulphonation capacity. This interaction could have clinical relevance since p-hydroxytriamterene sulphate is pharmacologically active.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Inhibidores de la Ciclooxigenasa/farmacología , Diflunisal/farmacología , Diuréticos/farmacocinética , Triantereno/farmacocinética , Adulto , Cromatografía Líquida de Alta Presión/métodos , Diuréticos/sangre , Diuréticos/orina , Interacciones Farmacológicas , Femenino , Humanos , Masculino , Persona de Mediana Edad , Triantereno/sangre , Triantereno/orinaRESUMEN
Metabolic disorders, medication, and diagnostic agents may be associated with urolithiasis in dogs. Examples of uroliths that have been uncommonly encountered in dogs include xanthine, dolomite, tetracycline, and sulfonamides. Detection of these and other apparently uncommon uroliths requires a high index of suspicion and proper methods of analysis.
Asunto(s)
Carbonato de Calcio/orina , Enfermedades de los Perros/etiología , Cálculos Urinarios/veterinaria , Xantinas/orina , Adenina/análogos & derivados , Adenina/orina , Animales , Enfermedades de los Perros/orina , Perros , Oxipurinol/orina , Sulfonamidas/orina , Tetraciclina/orina , Triantereno/orina , Cálculos Urinarios/etiología , Cálculos Urinarios/orinaRESUMEN
An efficient chromatographic method for the simultaneous determination of triamterene (TRI) and xipamide (XIP) in urine samples, based on high performance liquid chromatography with photodiode array detector (HPLC-DAD) has been developed. The HPLC separation was performed on a RP stainless-steel C-18 analytical column (250 mm × 4.6 mm, 5 µm) with a gradient elution system of 0.05 M phosphate buffer adjusted to pH 4.0 and methanol as the mobile phase. The method was used to determine the urinary excretion profile and to calculate different urinary pharmacokinetic parameters following oral dose of their combination compared with single oral doses of each drug and hence comparing their bioavailability. Quantitation was performed using chlorthalidone as internal standard. The calibration graphs of each drug were rectilinear in the range of 0.2-40 µg/mL urine for TRI and 0.2-15 µg/mL urine for XIP. An HPLC-DAD method was also successfully developed for the simultaneous determination of the investigated drugs in pharmaceutical preparations. The methods were validated in terms of linearity, accuracy, precision, selectivity, limits of detection and quantitation and other aspects of analytical validation.